DIVISION OF BIOEQUIVALENCE REVIEW

First Page		Document Content
Pharmaceutical sciences Medicine Dissolution testing Quality control Bioequivalence Mesalazine Generic drug Bioavailability Biopharmaceutics Classification System Pharmacology Pharmacokinetics Pharmaceutical industry		DIVISION OF BIOEQUIVALENCE REVIEW Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 66,65 KB Share Document on Facebook

	March 31, 2015 Ajinomoto Pharmaceuticals Co., Ltd. Kissei Pharmaceutical Co., Ltd. Ajinomoto Pharmaceuticals and Kissei announce partnership for joint development and marketing DocID: 1aH86 - View Document
	Brief apothekers inz mesalazine DocID: 16v8k - View Document
	Persbericht mesalazine meldpunt def DocID: 16fEb - View Document
	Persbericht mesalazine meldpunt def DocID: 16atb - View Document
	Aliment Pharmacol Ther 2005; 21: 1111–doi: j02458.x Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients DocID: 15ms7 - View Document